Abstract
Background Wastewater surveillance has been proposed as an epidemiological tool to define the prevalence and evolution of the SARS-CoV-2 epidemics. However, most implemented SARS-CoV-2 wastewater surveillance projects were relying on qPCR measurement of virus titers and did not address the mutational spectrum of SARS-CoV-2 circulating in the population.
Methods We have implemented a nanopore RNA sequencing monitoring system in the city of Nice (France, 550,000 inhabitants). Between October 2020 and March 2021, we monthly analyzed the SARS-CoV-2 variants in 113 wastewater samples collected in the main wastewater treatment plant and 20 neighborhoods.
Findings We initially detected the lineages predominant in Europe at the end of 2020 (B.1.160, B.1.177, B.1.367, B.1.474, and B.1.221). In January, a localized emergence of a variant (Spike:A522S) of the B.1.1.7 lineage occurred in one neighborhood. It rapidly spread and became dominant all over the city. Other variants of concern (B.1.351, P.1) were also detected in some neighborhoods, but at low frequency. Comparison with individual clinical samples collected during the same week showed that wastewater sequencing correctly identified the same lineages as those found in COVID-19 patients.
Interpretation Wastewater sequencing allowed to document the diversity of SARS-CoV-2 sequences within the different neighborhoods of the city of Nice. Our results illustrate how sequencing of sewage samples can be used to track pathogen sequence diversity in the current pandemics and in future infectious disease outbreaks.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
PB is supported by FRM (DEQ20180339158). The present work was possible thanks to the support of the National Infrastructure France Genomique (Commissariat aux Grands Investissements, ANR-10-INBS-09-03, ANR-10-INBS-09-02). BM is supported by Plan Cancer 2018 " ARN non-codants en cancerologie: du fondamental au translationnel " (Inserm number 18CN045) and Canceropole PACA.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The use of patient samples complied with French legislation. During the health emergency SARS-CoV-2 related patient data and laboratory results in France are recorded in the SARS-Cov2 Screening Information System SI-DEP ("Systeme Informations de DEPistage", French decree No. 2020-551 of May 12, 2020 ,Article 11 of Law No. 2020-546 of May 11, 2020 extending the state of health emergency). In the context of this law, patients can not object to the use of their SARS-CoV-2 related data for health surveys and epidemiological monitoring. Under this legislation, authorization of the use of patient data for research was granted unless patients actively express their opposition. A waiver of ethical approval was received from Mrs Elisabeth Huynh-Van, Data Protection Officer of the Nice University Hospital.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Competing Interests. The authors have read the journal’s policy and have the following competing interests: VL is employed by LBM Bioesterel, a Biogroup company. AL, ES and SL are employed by VEOLIA. There are no patents, products in development or marketed products associated with this research to declare.
Data Availability
All relevant data, custom software, R figures and analysis scripts are available on Github (https://github.com/ucagenomix/cagablea).
